Plain-English translation of NCT04615143 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a medication that helps your immune system fight cancer, can be given before surgery to help treat recurring liver cancer. The study is also testing whether combining this medication with another drug called Lenvatinib works even better. The goal is to shrink tumors before surgery and reduce the chance the cancer comes back afterward.
Liver cancer often comes back even after successful treatment, and most patients with recurring disease cannot have surgery. Researchers believe that this treatment might work better for recurring cancers than for new cancers, so they want to test whether giving it before surgery can help more patients and improve outcomes.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive the medication as an outpatient before surgery—either one drug alone or combined with a second drug, given over about 6 weeks. After your surgery, you will continue the same treatment for approximately one year. You will have regular clinic visits and scans to monitor how well the treatment is working and check for side effects.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Sun Yat-sen University
Enrollment target
~80 participants
Started
December 2020
Primary completion
December 2026
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in January 2025.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.